
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is a clinical-stage biotech company with a focus on developing precision medicine anti-cancer therapeutics for patients with high unmet medical needs. Its lead program, Stenoparib, is a promising drug that is being developed with a drug-specific companion diagnostic, leveraging its proprietary Drug Response Predictor (DRP) technology. Despite minimal current revenue, the company has a positive outlook due to its potential for significant growth and valuation in the future, while acknowledging the high risks involved in drug development. However, risks to its share price target include factors such as balance sheet and liquidity risks, failure to obtain regulatory approvals, and changes in macroeconomic factors and investor sentiment.
Bears say
Allarity Therapeutics is a clinical-stage biopharmaceutical company that utilizes its proprietary Drug Response Predictor (DRP) platform to improve patient selection for its lead program Stenoparib, currently in Phase 2 trials for ovarian and small cell lung cancer. While the company's focus on precision medicine is promising, there are concerns about the drug's long development timeline and commercialization risks, as well as the company's minimal revenue generation and debt levels. Despite potential for growth in the large PARP inhibitor market and positive clinical data, the analyst maintains a negative outlook due to these risks, adjusting estimates for EPS and maintaining a sell rating with a 12-month price target of $9.75 based on a NPV analysis.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares